| Active substance | abemaciclib |
| Holder | S.A. Eli Lilly N.V. |
| Status | closed |
| Indication | in combination with Endocrine Therapy as the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, nodepositive early breast cancer at high risk of recurrence |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 28/04/2023 |